EPIRUS Biopharmaceuticals Inc (EPRSQ)

0.00 USD  |  OTCM  |  Apr 23, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) 100.00%

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman’s disease. The group generally operates through the United States.
URL http://www.epirusbiopharma.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release N/A
Last Earnings Release May. 09, 2014
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman’s disease. The group generally operates through the United States.
URL http://www.epirusbiopharma.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release N/A
Last Earnings Release May. 09, 2014
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A